“showed a trend”

Although HRLNM showed a trend toward reduced RFS (113.5 vs. 124.6 months, p = 0.177), its impact on long-term survival remains uncertain.

The Maslach Burnout Inventory showed a trend toward improvement (15 vs. 11, p = 0.177), but was not statistically significant.

Individuals with a left tilt (−2.9 ± 0.4°) showed a trend toward improvement while being stimulated from their left CI (−2.0 ± 1.9°; paired t -test, p = 0.177), with no clear effects from right CI stimulation (−2.4 ± 1.5°; paired t -test, p > 0.99).

Kaplan-Meier analysis of GBC patients with HIF-1A + [median 10 months, mean 13.281 ± 1.612 months] showed a trend of shorter overall survival (OS) than that of HIF-1A - patients [median 13 months, mean 15.587 ± 1.400 months, p = 0.178, Figure 7 a ].

33 , 34 Wood and colleagues 33 showed a trend toward fewer bleeding complications (53% vs 63%, P = . 178) without increased risk of thrombosis (13% vs 21%, P = . 147) in patients supported on VA-ECMO who did not receive anticoagulation.

High dose group showed a trend to have higher incidence of grade 3–4 CRS than low dose group without reaching a statistical significance (8.4%, 95%CI −0.009–0.177; I 2 = 34.5%, p = 0.178 vs 1.6%, 95%CI −0.026–0.058; I 2 = 0.0%, p = .939) ( z = 1.53, P = .127) ( Figure 9(C) ). 3.4.

Group B showed a trend towards improvement at 3 months (+1.67 ± 1.16%, P = 0.178) and at 6 months (+2.07 ± 1.21%, P = 0.115), although these changes did not reach statistical significance.

The mistletoe group showed a trend toward less neutropenia ( p = 0.178) and improved pain and appetite loss scores ( p < 0.0001 and p = 0.047, respectively) while having positive, but not significant, impact on other EORTC QLQ-C30 scores.

Univariate analyses showed a trend towards a higher recurrence rate after procedures not performed under anti-TNF and/or immunomodulators [50.0% vs 75.0%; p = 0.178] or performed in patients who smoked [62.5% vs 18.8%, p = 0.073] [ Table 4 ].

Finally, animals treated with both Bev and βPix/COOL-1 siRNA-loaded RGD-NP showed a trend towards increased survival ( p = 0.1783), having an improved median survival of 100 days when compared with other treatment groups. 3.

7 Although there was no statistical significance compared to placebo, the median overall survival showed a trend toward favoring zoledronic acid (295 days for the 4 mg zoledronic acid group vs 216 days for the placebo group; P = 0.179). 7 These results suggest that zoledronic acid not only decreases SREs, but also improves survival in patients with bone metastatic RCC.

Patients with SARIFA-negative tumors showed a trend toward better progression-free survival (HR 1.357, 95% CI 0.869–2.118, p = 0.179) and disease-free survival (HR 1.648, 95% CI 0.802–3.383, p = 0.174) (Supplementary Fig.

Patients with baseline cGDF-15 levels above 0.8 ng/ml and increasing cGDF-15 levels after ICT showed a trend of a worse OS compared with patients with stable or decreasing cGDF-15 levels [mOS 14.13 months ( n = 29) versus 22.21 months ( n = 13), respectively, P = 0.1798].

Though not statistically significant, activated CD8 T-cells also showed a trend towards increased infiltration (p = 0.1799).

FdU treatment alone showed a trend toward enrichment for subsets of macrophages that were negative in expression of CD206 (Mac_II) and CD80 + CD86 + (Mac_VI) ( P = 0.18, P = 0.046).

HBV-positive patients showed a trend in favor of sorafenib rather than placebo for TTP (HR 0.74 CI 95% 0.48–1.14 p = 0.18) and OS (HR 0.74 CI 95% 0.544-1.03 p = 0.08) ( Figure 1C and Figure 1D ).

Survival analysis showed a trend for slower rates with MET-alone compared to control-alone mice ( Figure 2B ; p = 0.18).

The COPD cases showed a trend for accelerated aging compared to subjects without COPD (Estimate: 2.20; 95% CI: -1.04, 5.44; P=0.18, Table 3 ); however males demonstrated significant epigenetic age acceleration compared to females that stayed robust after adjustment with covariates in the multivariate model (Estimate: 1.98; 95% CI: 0.13, 3.83; P=0.036, Table 3 ).

The pooled estimate showed a trend toward fewer IH with mesh (OR 0.09 [0.00–3.13], p = 0.18), though this was not statistically significant.

Samples with the IKZF1 plus profile showed a trend of imatinib resistance ( P = .18; Dunn test; Figure 3 B).

1.5 months, HR 0.55, p < 0.001) and showed a trend toward prolonged median OS (15.1 vs. 8.0 months; HR 0.72, p = 0.18; overall population: 13.7 vs. 13.1 months, HR 0.93, p = 0.49) [ 38 ].

5.1 months; HR 0.53, p < 0.0001) and showed a trend toward improved OS (20.7 vs. 16.8 months, p = 0.18).

The American Society of Parenteral and Enteral Nutrition (ASPEN) recommends avoidance of IEN in high-risk patients based on 2 small RCTs which showed a trend towards higher mortality with IEN (13.9% IEN vs 7.4% CEN; p = 0.18) and increased risk of ventilator association pneumonia with IEN (49.3% IEN vs 30.9% CEN, p=0.02) [ 1 , 7 , 8 ].

In contrast, although the TMA cohort showed a trend for poorer survival with PD-L1 expression (33.3% vs. 71.4%, p = 0.18), this result did not achieve statistical significance ( Fig. 4A,B ).

Although not statistically significant, epidermal growth factor receptor positivity showed a trend toward greater frequency in inner lesions (46.7% vs 39.2%, P = .18), suggesting potential biological differences that warrant further investigation.